[Management of patients with pulmonary hypertension].
Due to the increased survival of patients with pulmonary hypertension, even non-cardiac anesthesiologists will see these patients more frequently for anesthesia. The hemodynamic goal in the perioperative period is to avoid an increase in pulmonary vascular resistance (PVR) and to reduce a possibly pre-existing elevated PVR. Acute increases of chronically elevated PVR may result from hypoxia, hypercapnia, acidosis, hypothermia, elevated sympathetic output and also release of endogenous or application of exogenous pulmonary vasoconstrictors. Early recognition and treatment of these changes might be life saving in these patients. Drug interventions to perioperatively reduce PVR include administration of pulmonary vasodilators, such as oxygen, prostacyclines (epoprostenol, iloprost), phosphodiesterase III (milrinone) and V (sildenafil) inhibitors, as well as nitrates and nitric oxide. Along with the concept of selective pulmonary vasodilation inhalative administration of pulmonary vasodilators has benefits compared to intravenous administration. New therapeutic strategies, such as inhalational iloprost, inhalational milrinone and intravenous sildenafil can be introduced without significant technical support even in smaller departments.
Department of Anesthesiology, Academic Medical Center AMC, Meibergdreef 9, 1100, Amsterdam, Niederlande. b.preckel@amc.uva.nl
B
B
Preckel
S
S
Eberl
J
J
Fräßdorf
M W
MW
Hollmann
D000758:Anesthesia; D006439:Hemodynamics / Q000502:physiology; D017052:Hospital Mortality; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D016343:Monitoring, Intraoperative; D019990:Perioperative Care; D018570:Risk Assessment; D012307:Risk Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents